Open Payments

Cedars-Sinai Medical Center

Type
Teaching hospital
Where
West Hollywood, CA
Medicare CCN
050625
Received
$21,345,357 in 1,283 records, 2022 ($5,501,286 general, $15,844,070 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment314$5,501,286
2022Research payment969$15,844,070

By company

CompanyRecordsAmountYears
Siemens Medical Solutions USA, Inc.15$3,687,5542022
Merck Sharp & Dohme LLC50$2,823,7532022
Boston Scientific Corporation72$2,006,8382022
Edwards Lifesciences Corporation65$1,618,5132022
Takeda Pharmaceuticals U.S.A., Inc.46$988,7232022
Celgene Corporation5$636,8592022
PFIZER INC.75$635,7852022
Eli Lilly and Company14$619,7732022
Alkermes, Inc.85$533,9822022
CSL Behring16$505,7612022
E.R. Squibb & Sons, L.L.C.21$475,7022022
Abbott Laboratories60$445,6792022
Janssen Research & Development, LLC32$420,8322022
Roche Diagnostics Operations, Inc.9$399,7652022
Jenavalve Technology, Inc.1$381,2202022
Genentech, Inc.12$252,2542022
Brahms GmbH12$246,4732022
MEDIVATION LLC.10$243,5022022
AstraZeneca Pharmaceuticals LP17$228,8722022
Blueprint Medicines Corporation5$190,8092022
Otsuka Pharmaceutical Co., Ltd.5$188,4172022
JAZZ PHARMACEUTICALS INC.3$170,5002022
ABBVIE INC.25$164,0242022
Beckman Coulter, Inc.1$150,0002022
Cardiovascular Systems Inc.10$148,1222022
Alnylam Pharmaceuticals Inc.10$140,0612022
Intuitive Surgical, Inc.22$139,7182022
PROGENICS PHARMACEUTICALS, INC.28$128,1882022
Medtronic, Inc.19$124,6812022
Grifols Therapeutics LLC14$121,8102022
Novartis Pharmaceuticals Corporation6$120,7412022
Zimmer Biomet Holdings, Inc.5$118,5242022
Intercept Pharmaceuticals, Inc.20$115,6202022
BioNTech SE24$96,1762022
Penumbra, Inc.13$81,5442022
Daiichi Sankyo Inc.6$73,4882022
SEAGEN INC.17$68,3782022
FUJIFILM Corporation1$68,0002022
KARL STORZ Endoscopy-America60$63,0312022
Stryker Corporation14$61,4712022
AstraZeneca UK Limited3$61,3052022
GE HEALTHCARE8$59,9252022
Travere Therapeutics, Inc.19$56,2462022
Janssen Scientific Affairs, LLC2$55,0002022
Astellas Pharma Global Development2$53,4942022
Horizon Therapeutics plc1$50,0002022
Biogen, Inc.3$49,8042022
Novocure Inc.5$48,3742022
VIVUS LLC2$48,0402022
Cook Medical LLC30$47,2262022

By nature of payment

NatureRecordsAmount
Research payment969$15,844,070
Royalty or License9$3,264,154
Grant75$1,180,142
Compensation for services other than consulting, including serving as faculty or as a speaker at a v12$401,770
Education62$180,108
Space rental or facility fees (teaching hospital only)76$166,610
Gift4$121,499
Long term medical supply or device loan30$115,688
Charitable Contribution31$49,726
Debt forgiveness14$20,235
Consulting Fee1$1,350

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Merck Sharp & Dohme LLC$417,204Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel2022
2022-12-31Merck Sharp & Dohme LLC$283,030Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase Ib,II Trial of anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma2022
2022-12-31Merck Sharp & Dohme LLC$189,005Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2022
2022-12-31Merck Sharp & Dohme LLC$143,913Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA SINGLE-CENTER OPEN-LABEL PROSPECTIVE PILOT STUDY OF POSACONAZOLE IN GENETICALLY-DEFINED PATIENTS WITH ACTIVE CROHN'S D2022
2022-12-31Merck Sharp & Dohme LLC$100,962Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2022
2022-12-31Merck Sharp & Dohme LLC$80,162Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT2022
2022-12-31Merck Sharp & Dohme LLC$60,451Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2022
2022-12-31Merck Sharp & Dohme LLC$22,125Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2022
2022-12-31Merck Sharp & Dohme LLC$17,648Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2022
2022-12-31Intuitive Surgical, Inc.$16,840Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2022
2022-12-31Merck Sharp & Dohme LLC$15,749Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with2022
2022-12-31Merck Sharp & Dohme LLC$15,338Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub2022
2022-12-31Merck Sharp & Dohme LLC$14,461Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in 2022
2022-12-31AngioDynamics, Inc.$13,000Long term medical supply or device loanIn-kind items and servicesSolero Device, Oncology2022
2022-12-31Merck Sharp & Dohme LLC$12,106Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel2022
2022-12-31KARL STORZ Endoscopy-America$10,367EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31Merck Sharp & Dohme LLC$9,962Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with2022
2022-12-31Merck Sharp & Dohme LLC$9,899Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2022
2022-12-31Merck Sharp & Dohme LLC$9,562Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2022
2022-12-31Merck Sharp & Dohme LLC$8,741Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2022
2022-12-31Brahms GmbH$6,000Research paymentIn-kind items and servicesBRAHMS KRYPTOR compact PLUS (instrument) Device, Kryptor instrumentIdentification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto2022
2022-12-31Merck Sharp & Dohme LLC$5,332Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub2022
2022-12-31Merck Sharp & Dohme LLC$5,030Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2022
2022-12-31Intuitive Surgical, Inc.$5,000EducationIn-kind items and servicesDAVINCI XI Device, SURGERY2022
2022-12-31Intuitive Surgical, Inc.$5,000EducationIn-kind items and servicesDAVINCI XI Device, SURGERY2022
2022-12-31Merck Sharp & Dohme LLC$4,785Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2022
2022-12-31Merck Sharp & Dohme LLC$4,758Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2022
2022-12-31Merck Sharp & Dohme LLC$4,541Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT2022
2022-12-31KARL STORZ Endoscopy-America$4,249EducationIn-kind items and services2022
2022-12-31Merck Sharp & Dohme LLC$4,023Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel2022
2022-12-31Merck Sharp & Dohme LLC$3,953Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as 2022
2022-12-31KARL STORZ Endoscopy-America$3,931EducationIn-kind items and services2022
2022-12-31Merck Sharp & Dohme LLC$3,659Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2022
2022-12-31COLOPLAST CORP$3,602Debt forgivenessCash or cash equivalentTitan Device, Men's Health2022
2022-12-31Merck Sharp & Dohme LLC$3,242Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2022
2022-12-31KARL STORZ Endoscopy-America$3,010Debt forgivenessIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$2,856EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31Intuitive Surgical, Inc.$2,720Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2022
2022-12-31Intuitive Surgical, Inc.$2,720Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2022
2022-12-31KARL STORZ Endoscopy-America$2,194EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$2,194EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$2,162EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$2,117EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31Stryker Corporation$2,068Long term medical supply or device loanIn-kind items and servicesSPY-PHI SYSTEM Device, ENDOSCOPY2022
2022-12-31COLOPLAST CORP$1,980Debt forgivenessCash or cash equivalentTitan Device, Men's Health2022
2022-12-31KARL STORZ Endoscopy-America$1,923EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$1,836EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31AstraZeneca Pharmaceuticals LP$1,765Research paymentIn-kind items and servicesLYNPARZA Drug, Oncology\";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in P2022
2022-12-31Merck Sharp & Dohme LLC$1,728Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with2022
2022-12-31AstraZeneca Pharmaceuticals LP$1,520Research paymentIn-kind items and servicesTAGRISSO Drug, OncologyTo assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P2022
2022-12-31Merck Sharp & Dohme LLC$1,450Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in 2022
2022-12-31KARL STORZ Endoscopy-America$1,308EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31AstraZeneca Pharmaceuticals LP$1,290Research paymentIn-kind items and servicesA Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr2022
2022-12-31KARL STORZ Endoscopy-America$1,203EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31Merck Sharp & Dohme LLC$1,079Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2022
2022-12-31Stryker Corporation$1,015Long term medical supply or device loanIn-kind items and services2022
2022-12-31Merck Sharp & Dohme LLC$988Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in 2022
2022-12-31ABBVIE INC.$981Research paymentIn-kind items and servicesStudy To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In2022
2022-12-31KARL STORZ Endoscopy-America$971EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31AstraZeneca UK Limited$961Research paymentIn-kind items and servicesAn open-label fixed sequence, study to assess the effect of repeated doses of capivasertib on the pharmacokinetics of or2022
2022-12-31KARL STORZ Endoscopy-America$898EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$898EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31Siemens Medical Solutions USA, Inc.$750Research paymentIn-kind items and servicesCSMC2019MRIPR785Xie2022
2022-12-31Merck Sharp & Dohme LLC$722Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2022
2022-12-31Merck Sharp & Dohme LLC$680Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as 2022
2022-12-31KARL STORZ Endoscopy-America$612EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31Stryker Corporation$573Long term medical supply or device loanIn-kind items and servicesLOVESEAT SLEEPER Device, FURNITURE2022
2022-12-31KARL STORZ Endoscopy-America$555Debt forgivenessIn-kind items and services2022
2022-12-31Merck Sharp & Dohme LLC$532Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as 2022
2022-12-31Brahms GmbH$519Research paymentIn-kind items and servicesBRAHMS PlGF plus KRYPTOR kits and BRAHMS sFlt-1 KRYPTOR kits Device, prenatal screeningIdentification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto2022
2022-12-31KARL STORZ Endoscopy-America$446EducationIn-kind items and services2022
2022-12-31Stryker Corporation$430Long term medical supply or device loanIn-kind items and servicesSYMMETRY II LOWBACK CHAIR W/ ARMS Device, FURNITURE2022
2022-12-31KARL STORZ Endoscopy-America$427EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$414EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31Merck Sharp & Dohme LLC$412Research paymentIn-kind items and servicesLYNPARZA Biological, ONCOLOGYA Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutatio2022
2022-12-31KARL STORZ Endoscopy-America$389EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$375EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$348EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31Stryker Corporation$340Debt forgivenessCash or cash equivalent2022
2022-12-31KARL STORZ Endoscopy-America$292EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$277EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$274EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$228Debt forgivenessIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$208EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31Medline Industries LP$159Debt forgivenessCash or cash equivalent2022
2022-12-31Merck Sharp & Dohme LLC$149Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2022
2022-12-31KARL STORZ Endoscopy-America$125EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$125EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$116EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$101EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31Brahms GmbH$55Research paymentIn-kind items and servicesBRAHMS KRYPTOR BUFFER and Solution 1, 4 Device, prenatal screeningIdentification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto2022
2022-12-31KARL STORZ Endoscopy-America$53EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$47EducationIn-kind items and services2022
2022-12-31KARL STORZ Endoscopy-America$45EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31Stryker Corporation$31Debt forgivenessCash or cash equivalent2022
2022-12-31KARL STORZ Endoscopy-America$22EducationIn-kind items and servicesHOPKINS Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$21EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31AstraZeneca Pharmaceuticals LP$18Research paymentIn-kind items and servicesTAGRISSO Drug, OncologyA Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Fact2022
2022-12-31KARL STORZ Endoscopy-America$16Long term medical supply or device loanIn-kind items and servicesn.a. Device, CLEANING STERILIZATION CARE2022
2022-12-31AstraZeneca Pharmaceuticals LP$15Research paymentIn-kind items and servicesIMFINZI Biological, OncologyThis is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus2022
2022-12-31KARL STORZ Endoscopy-America$12EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$10EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$8EducationIn-kind items and servicesn.a. Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$7EducationIn-kind items and services2022
2022-12-30Celgene Corporation$17,550Research paymentCash or cash equivalentExpanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commer2022
2022-12-30Janssen Research & Development, LLC$285Research paymentCash or cash equivalentA Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub2022
2022-12-29PFIZER INC.$9,250Research paymentCash or cash equivalentXTANDI Drug, ONCOLOGYA RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA2022
2022-12-28Boston Scientific Corporation$22,500GrantCash or cash equivalentGENERAL - THERAPIES Device, THERAPIES2022
2022-12-28Alkermes, Inc.$21,570Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-28Alkermes, Inc.$3,327Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-28Boston Scientific Corporation$1,500GrantCash or cash equivalentGENERAL - THERAPIES Device, THERAPIES2022
2022-12-28Alkermes, Inc.$557Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-28Alkermes, Inc.$557Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-28Alkermes, Inc.$520Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-28Alkermes, Inc.$390Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-28Alkermes, Inc.$260Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-28Alkermes, Inc.$260Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-28Alkermes, Inc.$234Research paymentCash or cash equivalentA Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously2022
2022-12-26Boston Scientific Corporation$21,160Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, ICACURATE IDE2022
2022-12-23Roche Products Limited$2,131Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyOBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT2022
2022-12-22Cook Medical LLC$27,000Charitable ContributionIn-kind items and servicesCOOK Device, HEMOSTASIS2022
2022-12-22Intercept Pharmaceuticals, Inc.$24,710Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyStudy of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC2022
2022-12-22Cook Medical LLC$5,150Charitable ContributionIn-kind items and servicesCOOK Device, HEMOSTASIS2022
2022-12-22Cook Medical LLC$1,120Charitable ContributionIn-kind items and servicesECHOTIP ULTRA Device, ENDOSCOPIC ULTRASOUND2022
2022-12-22Cook Medical LLC$1,050Charitable ContributionIn-kind items and servicesCOTTON-LEUNG Device, MISC. - NON-BILIARY2022
2022-12-22Cook Medical LLC$1,020Charitable ContributionIn-kind items and servicesCOTTON-LEUNG Device, BILIARY2022
2022-12-22Cook Medical LLC$912Charitable ContributionIn-kind items and servicesECHOTIP PROCORE Device, ENDOSCOPIC ULTRASOUND2022
2022-12-22Cook Medical LLC$906Charitable ContributionIn-kind items and servicesFUSION Device, BILIARY2022
2022-12-22Cook Medical LLC$876Charitable ContributionIn-kind items and servicesMEMORY BASKET Device, BILIARY2022
2022-12-22Cook Medical LLC$854Charitable ContributionIn-kind items and servicesFUSION Device, BILIARY2022
2022-12-22Cook Medical LLC$766Charitable ContributionIn-kind items and servicesSOEHENDRA Device, BILIARY2022
2022-12-22Cook Medical LLC$630Charitable ContributionIn-kind items and servicesECHOTIP Device, ENDOSCOPIC ULTRASOUND2022
2022-12-22Cook Medical LLC$510Charitable ContributionIn-kind items and servicesTHE WEB Device, BILIARY2022
2022-12-22Cook Medical LLC$502Charitable ContributionIn-kind items and servicesFUSION QUATTRO Device, BILIARY2022
2022-12-22Cook Medical LLC$502Charitable ContributionIn-kind items and servicesACROBAT Device, BILIARY2022
2022-12-22Cook Medical LLC$436Charitable ContributionIn-kind items and servicesCOTTON-LEUNG Device, MISC. - NON-BILIARY2022
2022-12-22Cook Medical LLC$430Charitable ContributionIn-kind items and servicesECHOTIP PROCORE Device, ENDOSCOPIC ULTRASOUND2022
2022-12-22Cook Medical LLC$428Charitable ContributionIn-kind items and servicesTRACER METRO Device, BILIARY2022
2022-12-22Cook Medical LLC$420Charitable ContributionIn-kind items and servicesSOEHENDRA Device, BILIARY2022
2022-12-22Cook Medical LLC$416Charitable ContributionIn-kind items and servicesCOOK Device, BILIARY2022
2022-12-22Cook Medical LLC$408Charitable ContributionIn-kind items and servicesROADRUNNER Device, BILIARY2022
2022-12-22Cook Medical LLC$404Charitable ContributionIn-kind items and servicesGLO-TIP Device, BILIARY2022
2022-12-22Cook Medical LLC$368Charitable ContributionIn-kind items and servicesFUSION Device, BILIARY2022
2022-12-22Cook Medical LLC$352Charitable ContributionIn-kind items and servicesSOEHENDRA Device, BILIARY2022
2022-12-22Cook Medical LLC$340Charitable ContributionIn-kind items and servicesFUSION Device, BILIARY2022
2022-12-22Cook Medical LLC$325Charitable ContributionIn-kind items and servicesECHOTIP Device, ENDOSCOPIC ULTRASOUND2022
2022-12-22Cook Medical LLC$279Charitable ContributionIn-kind items and servicesUTS Device, BILIARY2022
2022-12-22Cook Medical LLC$268Charitable ContributionIn-kind items and servicesFUSION OASIS Device, BILIARY2022
2022-12-22Cook Medical LLC$216Charitable ContributionIn-kind items and servicesSOEHENDRA Device, BILIARY2022
2022-12-22Cook Medical LLC$172Charitable ContributionIn-kind items and servicesGLO-TIP Device, BILIARY2022
2022-12-22Cook Medical LLC$166Charitable ContributionIn-kind items and servicesHUIBREGTSE KATON Device, BILIARY2022
2022-12-22SEAGEN INC.$99Research paymentCash or cash equivalentPhase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n2022
2022-12-22SEAGEN INC.$99Research paymentCash or cash equivalentPhase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n2022
2022-12-22SEAGEN INC.$99Research paymentCash or cash equivalentPhase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n2022
2022-12-22SEAGEN INC.$99Research paymentCash or cash equivalentPhase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n2022
2022-12-22SEAGEN INC.$99Research paymentCash or cash equivalentPhase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n2022
2022-12-22SEAGEN INC.$99Research paymentCash or cash equivalentPhase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n2022
2022-12-22SEAGEN INC.$99Research paymentCash or cash equivalentPhase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n2022
2022-12-21PFIZER INC.$16,608Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITU2022
2022-12-21Novartis Pharmaceuticals Corporation$13,382GrantCash or cash equivalent2022
2022-12-21Grifols Therapeutics LLC$780Research paymentCash or cash equivalentAlbutein Biological, Critical Care MedicineEffects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Li2022
2022-12-21Apellis Pharmaceuticals, Inc.$345Research paymentCash or cash equivalentMERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS2022
2022-12-21Grifols Therapeutics LLC$168Research paymentCash or cash equivalentAlbutein Biological, Critical Care MedicineEffects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Li2022
2022-12-20Otsuka Pharmaceutical Development & Commercialization, Inc.$22,500Research paymentCash or cash equivalentA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABIL2022
2022-12-20Roche Products Limited$3,247Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY2022
2022-12-20E.R. Squibb & Sons, L.L.C.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentOPDIVO Biological, Oncology2022
2022-12-20Kite Pharma, Inc.$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentYescarta Drug, CELLT2022
2022-12-19Merck Sharp & Dohme LLC$194,077Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2022
2022-12-19Boston Scientific Corporation$120,911Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTACURATE IDE2022
2022-12-19PFIZER INC.$88,502Research paymentCash or cash equivalentDAURISMO Drug, ONCOLOGYAN OPENLABEL PHASE 1B STUDY OF PF04449913 GLASDEGIB IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATE2022
2022-12-19Medtronic, Inc.$37,279Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-12-19Genentech, Inc.$15,236Research paymentCash or cash equivalent DrugA PHASE 2B EFFICACY SAFETY TRIAL OF PRASINEZUMAB IN PATIENTS WITH EARLY PARKINSON S DISEASE2022
2022-12-19Celgene Corporation$5,000GrantCash or cash equivalent2022
2022-12-19Boston Scientific Corporation$3,236Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAGENT IDE2022
2022-12-19Amryt Pharma Holdings Ltd$1,361Research paymentCash or cash equivalentMYCAPSSA Drug, EndocrinologyMACRO Registry2022
2022-12-19Boston Scientific Corporation$1,300Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAGENT IDE2022
2022-12-19PFIZER INC.$682Research paymentIn-kind items and servicesBRAFTOVI Drug, ONCOLOGYAN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY V2022
2022-12-19Boston Scientific Corporation$455Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAGENT IDE2022
2022-12-18PROGENICS PHARMACEUTICALS, INC.$2,500Long term medical supply or device loanIn-kind items and servicesPYLARIFY AI Device, Radiology DICOM Image Processing Application Software2022
2022-12-16Paragon 28, Inc.$11,450Research paymentCash or cash equivalentPhantom Hindfoot TTC/TC Nail System Device, Foot and Ankle ImplantsPhantom Hindfoot TTC/TC Nail System Post-Market Clinical Follow-Up Study2022
2022-12-16Genentech, Inc.$10,371Research paymentCash or cash equivalent DrugA PHASE 2B EFFICACY SAFETY TRIAL OF PRASINEZUMAB IN PATIENTS WITH EARLY PARKINSON S DISEASE2022
2022-12-16Takeda Pharmaceuticals U.S.A., Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-12-15Roche Diagnostics Operations, Inc.$250,000Research paymentCash or cash equivalent DeviceRD0063952022
2022-12-15Abbott Laboratories$11,400Research paymentCash or cash equivalent Device, Structural HeartClinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy2022
2022-12-15Abbott Laboratories$10,600Research paymentCash or cash equivalent Device, Structural HeartClinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy2022
2022-12-15E.R. Squibb & Sons, L.L.C.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentELIQUIS Drug, Cardiovascular2022
2022-12-15Eli Lilly and Company$706Research paymentIn-kind items and servicesAN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODER2022
2022-12-15Eli Lilly and Company$585Research paymentIn-kind items and servicesAN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS2022
2022-12-14Arthrex, Inc.$14,300Research paymentCash or cash equivalentSHOULDER SUTURE FIBERWIRE #2 FIBERWIRE Device, SHOULDER - SUTURE - FIBERWIRE - #2 FIBERWIREIIRR-01098_Biomechanical Evaluation of Posterolateral Corner Reconstruction with_IIBM/1002022
2022-12-14Intercept Pharmaceuticals, Inc.$1,872Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2022
2022-12-13MorphoSys AG$34,650Research paymentCash or cash equivalentMONJUVI Drug, OncologyA phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita2022
2022-12-13Travere Therapeutics, Inc.$2,002Research paymentCash or cash equivalent021FSGS160102022
2022-12-13Travere Therapeutics, Inc.$2,002Research paymentCash or cash equivalent021FSGS160102022
2022-12-12Edwards Lifesciences Corporation$33,879Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2022
2022-12-12Janssen Research & Development, LLC$6,943Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2022
2022-12-12E.R. Squibb & Sons, L.L.C.$50Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant Melanoma Monotherapy2022
2022-12-11Applied Medical Resources Corporation$18,500Research paymentCash or cash equivalentVoyant electrosurgical generator Device, VOYANT SYSTEMSApplied Medical Voyant2022
2022-12-11Abbott Laboratories$349Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-12-09Janssen Research & Development, LLC$14,183Research paymentCash or cash equivalentERLEADA Drug, OncologyA Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall2022
2022-12-09Janssen Research & Development, LLC$14,183Research paymentCash or cash equivalentERLEADA Drug, OncologyA Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall2022

The latest 200 records of 1,283.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Los Angeles CountyWest Hollywood city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In West Hollywood, CA, county Los Angeles County, CA, state California; placed by its city name.

MeasurePlace (city or town)
West Hollywood, CA
County
Los Angeles County, CA
State
California
Population B0100334,8849,808,66739,287,377
Population, 2020 census P135,75710,014,00939,538,223
Median age B0100240.038.237.9
Under 18 B010013.6%20.6%22.0%
65 and over B0100116.8%15.2%15.7%
Households B1100122,9203,416,44913,548,091
Foreign born B0500223.6%33.4%27.0%
Median household income B19013$96,995$90,112$99,122
Median family income B19113$126,364$101,573$113,346
Per capita income B19301$90,080$45,792$49,513
Poverty rate B1700112.9%13.7%12.0%
Unemployment rate B230258.9%7.3%6.6%
Civilian labor force B2302525,8185,200,65620,068,466
Mean commute (minutes) B0801327.130.428.7
Bachelor's degree or higher B1500364.2%36.0%37.1%
Housing units B2500126,0793,650,46614,644,735
Owner-occupied B2500319.8%45.9%55.9%
Renters B2500380.2%54.1%44.1%
Median home value B25077$924,800$834,200$734,700
Median gross rent B25064$2,091$1,954$2,036
White, not Hispanic B0300269.5%24.7%33.8%
Black B030024.3%7.4%5.2%
Hispanic or Latino B0300213.1%48.4%40.2%
Asian B030026.1%14.9%15.3%
American Indian and Alaska Native B030020.1%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in West Hollywood, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.